Serum amylin level in Behçet’s disease and relation to parameters of metabolic syndrome and disease activity

Abstract EN

Background Insulin resistance is found in Behçet’s disease and associated with the development of metabolic syndrome.

Our study explored whether amylin, which is involved in insulin resistance and development of metabolic syndrome, is observed in patients with Behçet’s disease.

Aim Our aim was to assess serum levels of amylin in patients with Behçet’s disease and evaluate its relation to metabolic syndrome.

Patients and methods Thirty Behçet’s disease patients and 30 controls matched by age, sex, and BMI were studied.

The disease activity was assessed using the Behçet’s disease Current Activity Form score.

Serum amylin level was studied using the enzymelinked immunosorbent assay method.

Results Our result showed that 11 (36.6%) patients under study were diagnosed with the metabolic syndrome, and there were significant differences between Behçet’s cases and control groups in cholesterol, triglyceride, and low-density lipoprotein levels (P<0.05).

Amylin level was 392.2 μg/dl in Behçet’s cases compared with 659.9 μg/ dl in the control group.

The difference was statistically significant at P value less than 0.05.

There was a negative correlation between amylin levels and parameters of metabolic syndrome, a significant difference in amylin levels between Behçet’s patients with an active manifestation and patient with an inactive manifestation.

Conclusion Amylin serum levels were significantly lower in patients with Behçet’s disease, indicating that this hormone could be a factor for the development of metabolic syndrome in Behçet’s disease.